Lupitidine
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H27N5O2S |
| Molar mass | 413.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lupitidine (INN; lupitidine hydrochloride (USAN); development code SKF-93479) is a long-acting H2 receptor antagonist[1] developed by Smith, Kline & French and described as an antiulcerogenic that was never marketed.[2] It was shown to inhibit nocturnal gastric acid secretion[3] and, in experiments on rodents, produced diffuse neuroendocrine cell hyperplasia and an increase in multifocal glandular hyperplasia due to hypergastrinemia resulting from the pharmacological suppression of gastric acid secretion.[4]
References
[edit]- ^ Franzén L, Ghassemifar R, Malcherek P (July 1991). "Experimental mast cell activation improves connective tissue repair in the perforated rat mesentery". Agents and Actions. 33 (3–4): 371–7. doi:10.1007/bf01986588. PMID 1683107. S2CID 23827166.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 745–. ISBN 978-1-4757-2085-3.
- ^ Dammann HG, Müller P, Simon B (January 1982). "Inhibition of nocturnal acid secretion by H2-receptor-antagonist SKF 93479". Lancet. 1 (8265): 224. doi:10.1016/S0140-6736(82)90788-7. PMID 6119582. S2CID 5525326.
- ^ Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P (1 February 1988). "Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole". Toxicologic Pathology. 16 (2): 288–98. doi:10.1177/019262338801600222. PMID 2903544.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |